Quigg R - Search Results

1

Renin-Angiotensin-Aldosterone System Blockers in Elderly Adults with Chronic Kidney Disease without Diabetes Mellitus or Proteinuria.

Arora P, Golzy M, Patel N, Quigg R, Carter RL, Lohr JW. Arora P, et al. Among authors: quigg r. J Am Geriatr Soc. 2015 Dec;63(12):2478-2484. doi: 10.1111/jgs.13842. J Am Geriatr Soc. 2015. PMID: 26691698

2

The role of the renin-angiotensin system in cholesterol and puromycin mediated renal injury.

Ghosh S, Sica D, Schoolwerth AC, Quigg RJ, Haas M, Fakhry I, Gehr TW. Ghosh S, et al. Am J Med Sci. 2002 Dec;324(6):296-304. doi: 10.1097/00000441-200212000-00002. Am J Med Sci. 2002. PMID: 12495295

3

Immunoregulation of inflammation in chronic kidney disease.

Takase O, Iwabuchi K, Quigg RJ. Takase O, et al. J Immunol Res. 2014;2014:897487. doi: 10.1155/2014/897487. Epub 2014 Feb 9. J Immunol Res. 2014. PMID: 24741630 Free PMC article. No abstract available.

4

Molecular characterization of rat glomerular epithelial cell complement receptors.

Quigg RJ, Sneed AE 3rd. Quigg RJ, et al. J Am Soc Nephrol. 1994 May;4(11):1912-9. doi: 10.1681/ASN.V4111912. J Am Soc Nephrol. 1994. PMID: 7919144

5

Renal FcRn reclaims albumin but facilitates elimination of IgG.

Sarav M, Wang Y, Hack BK, Chang A, Jensen M, Bao L, Quigg RJ. Sarav M, et al. J Am Soc Nephrol. 2009 Sep;20(9):1941-52. doi: 10.1681/ASN.2008090976. Epub 2009 Aug 6. J Am Soc Nephrol. 2009. PMID: 19661163 Free PMC article.

6

Chronic kidney disease, uremic milieu, and its effects on gut bacterial microbiota dysbiosis.

Chaves LD, McSkimming DI, Bryniarski MA, Honan AM, Abyad S, Thomas SA, Wells S, Buck M, Sun Y, Genco RJ, Quigg RJ, Yacoub R. Chaves LD, et al. Among authors: quigg rj. Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F487-F502. doi: 10.1152/ajprenal.00092.2018. Epub 2018 Apr 25. Am J Physiol Renal Physiol. 2018. PMID: 29693447 Free PMC article.

7

Contrasting effects of systemic monocyte/macrophage and CD4+ T cell depletion in a reversible ureteral obstruction mouse model of chronic kidney disease.

Chaves LD, Mathew L, Shakaib M, Chang A, Quigg RJ, Puri TS. Chaves LD, et al. Clin Dev Immunol. 2013;2013:836989. doi: 10.1155/2013/836989. Epub 2013 Dec 31. Clin Dev Immunol. 2013. PMID: 24489579 Free PMC article.

8

Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice.

Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, Quigg RJ. Bao L, et al. J Am Soc Nephrol. 2003 Mar;14(3):670-9. doi: 10.1097/01.asn.0000051597.27127.a1. J Am Soc Nephrol. 2003. PMID: 12595503

9

Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation.

Bao L, Zhou J, Holers VM, Quigg RJ. Bao L, et al. J Am Soc Nephrol. 2003 Oct;14(10):2516-25. doi: 10.1097/01.asn.0000089831.96794.0b. J Am Soc Nephrol. 2003. PMID: 14514729

10

Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes.

Park P, Haas M, Cunningham PN, Bao L, Alexander JJ, Quigg RJ. Park P, et al. Am J Physiol Renal Physiol. 2002 Feb;282(2):F352-7. doi: 10.1152/ajprenal.00160.2001. Am J Physiol Renal Physiol. 2002. PMID: 11788450 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

206 results

Search Page